PERTEN

Información principal

  • Denominación comercial:
  • PERTEN 1% GEL TOPICO
  • Dosis:
  • 1%
  • formulario farmacéutico:
  • GEL
  • Usar para:
  • Humanos
  • Tipo de medicina:
  • medicamento alopático
  • Fabricado por:
  • MEYER PRODUCTOS TERAPEUTICOS S.A

Documentos

Localización

  • Disponible en:
  • PERTEN 1% GEL TOPICO
    Venezuela
  • Idioma:
  • español

Otros datos

Estado

  • Fuente:
  • Instituto Nacional de Higiene - República Bolivariana de Venezuela
  • Estado de Autorización:
  • VIGENTE
  • Número de autorización:
  • E.F.40.673
  • Fecha de autorización:
  • 13-05-2014
  • última actualización:
  • 03-09-2018

Prospecto

15-11-2018

Drug Safety Update , Noviembre 2018

MHRA , 14 de noviembre de 2018 Hidroclorotiazida: riesgo de cáncer de piel no melanoma Sildenafil: hipertensión pulmonar persistente del recién nacido Fluoroquinolonas: aneurisma y disección aórtica

REDCIMLAC - Red de Centros de Información de Medicamentos de Latinoamérica y el Caribe

8-11-2018

Identifican un nuevo mecanismo molecular responsable del envejecimiento del corazón

Identifican un nuevo mecanismo molecular responsable del envejecimiento del corazón

Un estudio dirigido por Marisol Ruiz-Meana, investigadora principal del grupo de Enfermedades Cardiovasculares del Vall d’Hebron Institut de Recerca (VHIR) que dirige David García-Dorado, en el que ha participado el Grupo de Química de Proteínas del Centro Nacional de Investigación Cardiovascular (CNIC), ambos pertenecientes al CIBERCV, ha descubierto que las alteraciones funcionales de las células […]

Cuba - infomed - Red de Salud de Cuba

5-7-2018

Recall of valsartan blood pressure medicine

Recall of valsartan blood pressure medicine

Impurities that could potentially be harmful to health have been found in variants of medicines containing the active substance valsartan. The medicine is used to treat hypertension and heart failure. Patients treated with these medicines are therefore advised to contact their doctor as soon as possible to be switched to another type of medicine.

Danish Medicines Agency

25-5-2018

Orphan designation:  Treprostinil sodium,  for the: Treatment of chronic thromboembolic pulmonary hypertension

Orphan designation: Treprostinil sodium, for the: Treatment of chronic thromboembolic pulmonary hypertension

On 8 February 2013, orphan designation (EU/3/13/1103) was granted by the European Commission to SciPharm S.a.r.L, Luxembourg, for treprostinil sodium for the treatment of chronic thromboembolic pulmonary hypertension.

Europe - EMA - European Medicines Agency

24-5-2018

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

FDA Approves Semintra, the First FDA-approved Animal Drug for the Control of Systemic Hypertension in Cats

The FDA has approved Semintra (telmisartan oral solution), the first FDA-approved animal drug to control systemic hypertension in cats. Semintra is an oral solution administered either directly into the cat’s mouth or on top of a small amount of food.

FDA - U.S. Food and Drug Administration

14-6-2010

Change of the reimbursement for certain cardiovascular products as of 15 November 2010

Change of the reimbursement for certain cardiovascular products as of 15 November 2010

The Reimbursement Committee and the Danish Medicines Agency have reviewed some of the medicinal products used for the treatment of cardiovascular disease (antihypertensives) in order to assess whether they meet the criteria for public reimbursement. The medicinal products concerned are the so-called angiotensin II antagonists and renin inhibitors.

Danish Medicines Agency

9-6-2009

Changes in reimbursement for cardiovascular medicine as of 13 July 2009

Changes in reimbursement for cardiovascular medicine as of 13 July 2009

The Reimbursement Committee and the Danish Medicines Agency have reviewed medicinal products for the treatment of cardiovascular disease (‘antihypertensives’) in order to assess whether they meet the

Danish Medicines Agency

21-11-2008

Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases

Consultation responses on the future reimbursement status of medicinal products for cardiovascular diseases

The Reimbursement Committee’s additional recommendation concerning the future reimbursement status of medicinal products for cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensives) was submitted for consultation with 19 September 2008 as the consultation deadline

Danish Medicines Agency

8-9-2008

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

Reassessment of reimbursement status of medicinal products for cardiovascular diseases – additional recommendation from the Reimbursement Committee

The Danish Medicines Agency has asked the Reimbursement Committee to reassess the reimbursement status of medicinal products authorised for marketing in Denmark in the ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

7-7-2008

Consultation responses to the recommendation about the reimbursement status for medicinal products for the treatment cardiovascular diseases

Consultation responses to the recommendation about the reimbursement status for medicinal products for the treatment cardiovascular diseases

The Reimbursement Committee's recommendation about the future reimbursement status of medicinal products for the treatment of cardiovascular diseases in ATC groups C02, C03, C07, C08 and C09 (antihypertensive drugs) was submitted for consultation on 5 May 2008.

Danish Medicines Agency

14-2-2008

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Reassessment of reimbursement status for medicinal products for the treatment of cardiovascular diseases

Following a request from the Danish Medicines Agency, the Reimbursement Committee has reassessed the reimbursement status for medicinal products authorised for marketing in Denmark in ATC groups C02 (antihypertensives), C03 (diuretics), C07 (beta blocking agents), C08 (calcium channel blockers) and C09 (ACE inhibitors, angiotensin II antagonists and renin inhibitors).

Danish Medicines Agency

18-12-2006

Reassessment of reimbursement status for medicinal products for hypertension

Reassessment of reimbursement status for medicinal products for hypertension

In March 2006, the Danish Medicines Agency contacted a number of scientific societies to clarify certain aspects of the treatment of hypertension in Denmark.

Danish Medicines Agency

18-12-2006

Reimbursement status of medicinal products aginst hypertension

Reimbursement status of medicinal products aginst hypertension

On 6 March 2006, the Danish Medicines Agency wrote a letter to a number of scientific societies to make them clarify certain aspects of the treatment of hypertension in Denmark.

Danish Medicines Agency

24-4-2006

Letter to scientific societies on treatment of hypertension

Letter to scientific societies on treatment of hypertension

As part of the reassessment concerning medicinal products' reimbursement status, the Danish Medicines Agency has begun looking at reimbursement status of medicinal products for hypertension.

Danish Medicines Agency

24-5-2018

Want a #HealthyHeart? Get moving! Here are some ways you can #MoveWithHeart today!  http://bit.ly/2II1XR2  #MoveInMay #HypertensionMonthpic.twitter.com/3teHPIlA40

Want a #HealthyHeart? Get moving! Here are some ways you can #MoveWithHeart today! http://bit.ly/2II1XR2  #MoveInMay #HypertensionMonthpic.twitter.com/3teHPIlA40

Want a #HealthyHeart? Get moving! Here are some ways you can #MoveWithHeart today! http://bit.ly/2II1XR2  #MoveInMay #HypertensionMonth pic.twitter.com/3teHPIlA40

FDA - U.S. Food and Drug Administration